{"id":755,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"bremelanotide-reconnect-phase-3-trials-and-fda-label","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","title":{"rendered":"Ensayos de Bremelanotida RECONNECT: criterios de valoraci\u00f3n, seguridad y alcance de FDA"},"content":{"rendered":"

La bremelanotida tiene un historial real de f\u00e1rmacos terminados aprobados por FDA, pero su alcance es limitado. Los ensayos RECONNECT estudiaron a mujeres premenop\u00e1usicas con HSDD adquirido y generalizado (no a hombres), mejora del rendimiento o un material de investigaci\u00f3n gen\u00e9rico de PT-141.<\/p>

Evidencia de un vistazo<\/h2>
  • Los ensayos 3 de dos fases asignaron al azar a mujeres 1,267; 1,202 estaban en la poblaci\u00f3n de eficacia.<\/li>
  • Los cambios entre grupos favorecieron a la bremelanotida para los puntos finales de deseo y angustia, pero una medida de evento satisfactorio post hoc no difiri\u00f3 significativamente.<\/li>
  • Se produjeron n\u00e1useas, enrojecimiento y dolor de cabeza al menos en 10% y fueron m\u00e1s frecuentes que con el placebo.<\/li><\/ul><\/div><\/div>
    \"Visualizaci\u00f3n
    Ilustraci\u00f3n original de investigaci\u00f3n editorial. No es una figura de estudio, una imagen de un paciente, una fotograf\u00eda de un producto, un resultado de ensayo suministrado ni una representaci\u00f3n de un lote de cat\u00e1logo.<\/figcaption><\/figure>

    Registro de estudio<\/h2>

    Los criterios de valoraci\u00f3n coprimarios fueron el cambio en la puntuaci\u00f3n del dominio del deseo de FSFI y un \u00edtem de angustia del FSDS-DAO. Las diferencias de deseo espec\u00edficas del estudio fueron 0.30 y 0.42; las diferencias de angustia fueron \u22120.37 y \u22120.29. La significancia estad\u00edstica no describe por s\u00ed sola el tama\u00f1o o la relevancia del beneficio para cada individuo.<\/p>

    Dise\u00f1o<\/strong>Dos ensayos id\u00e9nticos de fase 3, aleatorizados, doble ciego y controlados con placebo<\/span><\/div>
    Aleatorizado<\/strong>1,267 mujeres premenop\u00e1usicas<\/span><\/div>
    Diferencia de deseo integrada<\/strong>0.35 versus placebo; P<0.001<\/span><\/div>
    Diferencia de angustia integrada<\/strong>\u22120.33 versus placebo; P<0.001<\/span><\/div>
    L\u00edmite de etiqueta<\/strong>No indicado para mujeres posmenop\u00e1usicas, hombres, ni\u00f1os ni para mejora del rendimiento.<\/span><\/div><\/div><\/div>

    Resultados en contexto<\/h2>

    El art\u00edculo no informa diferencias grupales significativas en el porcentaje de eventos sexuales satisfactorios en un an\u00e1lisis post-hoc. Preservar ese hallazgo nulo mantiene el registro m\u00e1s informativo que un resumen solo de beneficios.<\/p>

    El etiquetado actual de DailyMed identifica a Vyleesi como inyecci\u00f3n de bremelanotida bajo NDA 210557 y enumera el aumento transitorio de la presi\u00f3n arterial, la disminuci\u00f3n de la frecuencia card\u00edaca, las n\u00e1useas y la hiperpigmentaci\u00f3n focal entre informaci\u00f3n de seguridad importante. Esta etiqueta pertenece a la formulaci\u00f3n aprobada, no a un art\u00edculo del cat\u00e1logo de investigaci\u00f3n.<\/p>

    Lo que la evidencia no puede establecer<\/h2>

    La poblaci\u00f3n de evidencia y la indicaci\u00f3n son espec\u00edficas; afirmaciones m\u00e1s amplias sobre el desempe\u00f1o sexual no est\u00e1n respaldadas.<\/p>

    Los ensayos fundamentales fueron financiados por la industria.<\/p>

    Una fracci\u00f3n activa aprobada no convierte a un material de origen independiente en un medicamento aprobado.<\/p>","protected":false},"excerpt":{"rendered":"

    La bremelanotida tiene un historial real de f\u00e1rmacos terminados aprobados por FDA, pero su alcance es limitado. Los ensayos RECONNECT estudiaron a mujeres premenop\u00e1usicas con HSDD adquirido y generalizado (no a hombres), mejora del rendimiento o un material de investigaci\u00f3n gen\u00e9rico de PT-141.<\/p>","protected":false},"author":1,"featured_media":739,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"358","pim_article_type":"Published evidence review","pim_evidence_level":"Two randomized phase 3 trials plus current FDA-approved prescribing information","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"RECONNECT bremelanotide phase 3 trials\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31599840\/\",\"note\":\"Primary phase 3 publication; PMID 31599840.\"},{\"title\":\"DailyMed Vyleesi prescribing information\",\"url\":\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf\",\"note\":\"Current FDA-approved finished-drug label.\"},{\"title\":\"PubChem Bremelanotide record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bremelanotide\",\"note\":\"Free-base peptide identity; CID 9941379.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\nBremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope<\/title>\n<meta name=\"description\" content=\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\" \/>\n<meta property=\"og:description\" content=\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\",\"name\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Regulatory and two-trial evidence visualization for bremelanotide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ensayos de Bremelanotida RECONNECT: criterios de valoraci\u00f3n, seguridad y alcance de FDA","description":"La bremelanotida tiene un historial real de f\u00e1rmacos terminados aprobados por FDA, pero su alcance es limitado. Los ensayos RECONNECT estudiaron a mujeres premenop\u00e1usicas con enfermedades adquiridas, gene...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","og_locale":"es_ES","og_type":"article","og_title":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope","og_description":"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026","og_url":"https:\/\/nhdbio.com\/es\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","articleSection":["Published Study Reviews"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","url":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","name":"Ensayos de Bremelanotida RECONNECT: criterios de valoraci\u00f3n, seguridad y alcance de FDA","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"La bremelanotida tiene un historial real de f\u00e1rmacos terminados aprobados por FDA, pero su alcance es limitado. Los ensayos RECONNECT estudiaron a mujeres premenop\u00e1usicas con enfermedades adquiridas, gene...","breadcrumb":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","width":1672,"height":941,"caption":"AI-generated illustration: Regulatory and two-trial evidence visualization for bremelanotide"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=755"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/755\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/739"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}